The Independent is an important voice in the community of readers and writers dedicated to book reviews and writing about the world of books.

The content discusses the book "Curved Air" by Kevin Davies, exploring the complexities surrounding sickle cell disease (SCD). It highlights the historical context of SCD, its painful effects, and the stigma associated with it being regarded as a 'Black disease.' Davies emphasizes the urgency for further research and eventual cures, particularly after advancements like CRISPR gene-editing. The review suggests that although the book is informative, it may overwhelm some readers with technical language and could benefit from clearer presentations of complex ideas. The book is highly recommended for those seeking to understand SCD more deeply.

YouTube video by the bumbling biochemist

How sickle cell anemia led the quest to edit the human genome while patients endured decades of racial discrimination and medical neglect.In December 1904, Walter Clement Noel, a dental student from G...

Get tickets and support People's Book by becoming a member

The puppies represent a key first step towards addressing canine allergenicity and mark potentially a significant advance in veterinary biotechnology.

Parents want accountability after study went disastrously wrong, Science and Retraction Watch investigation reveals

Davies (Editing Humanity), executive editor of The CRISPR Journal, delivers a captivating history of the century-long effort to ...

The entrepreneur was also a pioneer of synthetic biology. The entrepreneur was also a pioneer of synthetic biology.

One of the winners of the 2026 ASGCT Catalyst Award, Kiran Musunuru, MD, PhD, delivered a sobering lecture on the legacy of the Baby KJ story and the real-world discussions with the FDA to streamline ...

In the first of a new series of GEN Keynote Webinars, Professor Rodolphe Barrangou, PhD (North Carolina State; EIC, The CRISPR Journal) offers a front-row perspective of the CRISPR revolution, the sem...

In the first of a new series of GEN Keynote Webinars, Professor Rodolphe Barrangou, PhD (North Carolina State; EIC, The CRISPR Journal) offers a front-row perspective of the CRISPR revolution, the sem...

The draft guidance was unveiled in a briefing held at HHS headquarters in Washington DC, hosted by HHS Secretary Robert F. Kennedy, Jr., and the Commissioner of the U.S. Food and Drug Administration (...

A personal reflection on the life, legacy, and controversies of DNA co-discoverer James Watson, following his death at age 97.

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of editing human embryos to make disease-free children.

Artificial intelligence (AI) and machine learning partnered with big data generation at unprecedented scale is transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. From generative AI to unlock novel drug candidates to virtual cells that gleam insights across multimodal biology, we are witnessing the cusp of an exponential curve of AI innovation that is poised to enhance and perhaps overhaul the design and validation of novel therapeutics. In 2024, GEN debuted our virtual summit, The State of AI in Drug Discovery, which drew a record audience. This year’s summit provides a platform for an outstanding group of researchers, evangelists and entrepreneurs to showcase the latest advances, applications and challenges regarding the deployment of AI across therapeutic development. The program features many of the most exciting companies and organizations powering the AI revolution, including NVIDIA, Xaira Therapeutics, Recursion, Chan Zuckerberg Initiative, Arc Institute, Generate: Biomedicines, and more! Please join us on October 29th for a dynamic program featuring: A featured presentation with Bo Wang, PhD (Xaira Therapeutics) on the promise of multimodal AI for health care The democratization of small molecule drug discovery with the developers of Boltz-2, Gabriele Corso, PhD (MIT), Regina Barzilay, PhD (MIT), and Najat Khan, PhD (Recursion) Evolving industry trends across the AI therapeutic landscape with Derek Lowe, PhD (Novartis and author of "In the Pipeline"), Molly Gibson, PhD, (Flagship Pioneering), and Stacie Calad-Thomson, PhD (NVIDIA) Building the virtual cell with Theofanis Karaletsos (Chan Zuckerberg Initiative), Emma Lundberg, PhD (Stanford), Hani Goodarzi, PhD (Arc Institute), and Ron Alfa, MD, PhD (Noetik) What’s next for AI in protein design with Surge Biswas, PhD (Nabla Bio), Tharindi Hapuarachchi, PhD (Generate: Biomedicines), and Oliver Vince, PhD (Basecamp Research) Breakout sessions from our event sponsors, Revvity Signals, Benchling, and Telesis Bio. Registration for The State of AI in Drug Discovery is entirely free. Sponsored by

It has been 20 years since the term “genome editing” first entered the scientific lexicon. The technology was transformed by the development of CRISPR gene editing in 2012. But the remarkable pace of progress in the first decade has hit some headwinds of late. In particular, the use of CRISPR as a clinical tool has progressed more slowly than anticipated, putting pressure on many gene editing companies to narrow their pipelines to conserve resources and highlighting the uphill challenge to deliver the potential of CRISPR to patients worldwide. Nevertheless, new discoveries are expanding the gene editing toolbox in novel and exciting directions. In The State of CRISPR and Genome Editing virtual summit, GEN brings together an outstanding line-up of pioneers and practitioners in genome editing to provide a compelling and candid overview of the field. Attendees will hear about the latest scientific, technology, commercial and regulatory advances that will enable genome editing to unleash its full potential in the clinic and beyond. Highlights of this summit include:A keynote lecture from Feng Zhang PhD (Broad Institute) on precision genome editing with and without CRISPR.Beth Shapiro PhD (Colossal Biosciences) discusses gene editing milestones, de-extinction and dire wolves. Fyodor Urnov PhD (Innovative Genomics Institute) on the path to achieving CRISPR cures for hundreds of rare genetic diseases. The state of cell and gene therapy in Africa with Julie Makani MD PhD (Tanzania) and Johnny Mahlangu (South Africa).A conversation on base editing and more with Alexis Komor PhD (UC San Diego) and Nicole Gaudelli PhD (Google Ventures).Neville Sanjana PhD (New York Genome Ctr) on new CRISPRs to probe the human non-coding genome.Breakout sessions from the summit sponsors. Registration is free! Join us on June 11 for The State of CRISPR & Genome Editing. Sponsored by:

In a scathing public letter, employees of the National Institutes of Health accused the administration of undermining the agency’s work and endangering people’s health.

Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary roundtable conducted by the FDA in front of its recently-appointed top offi...

Captioning Link: https://bit.ly/4dQaNaz

Three hundred and seven days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being treated.

How the administration is breaking the government, and what that means for all of us.

A new supercomputer named after a winner of the Nobel Prize in chemistry will help power artificial intelligence technology and scientific discoveries from a perch in the hills above the University of...

Statement Global Observatory for Genome Editing Summit Statement: Call for a Charter on Emerging Technologies and Human Dignity May 23, […]

Oscar winner Natalie Portman is set to star in Photograph 51 for The King's Speech director Tom Hooper.

It has been 20 years since the term “genome editing” first entered the scientific lexicon. The technology was transformed by the development of CRISPR gene editing in 2012. But the remarkable pace of progress in the first decade has hit some headwinds of late. In particular, the use of CRISPR as a clinical tool has progressed more slowly than anticipated, putting pressure on many gene editing companies to narrow their pipelines to conserve resources and highlighting the uphill challenge to deliver the potential of CRISPR to patients worldwide. Nevertheless, new discoveries are expanding the gene editing toolbox in novel and exciting directions. In The State of CRISPR and Genome Editing virtual summit, GEN brings together an outstanding line-up of pioneers and practitioners in genome editing to provide a compelling and candid overview of the field. Attendees will hear about the latest scientific, technology, commercial and regulatory advances that will enable genome editing to unleash its full potential in the clinic and beyond. Highlights of this summit include:A keynote lecture from Feng Zhang PhD (Broad Institute) on precision genome editing with and without CRISPR.Beth Shapiro PhD (Colossal Biosciences) discusses gene editing milestones, de-extinction and dire wolves. Fyodor Urnov PhD (Innovative Genomics Institute) on the path to achieving CRISPR cures for hundreds of rare genetic diseases. The state of cell and gene therapy in Africa with Julie Makani MD PhD (Tanzania) and Johnny Mahlangu (South Africa).A conversation on base editing and more with Alexis Komor PhD (UC San Diego) and Nicole Gaudelli PhD (Google Ventures).Neville Sanjana PhD (New York Genome Ctr) on new CRISPRs to probe the human non-coding genome.Breakout sessions from the summit sponsors. Registration is free! Join us on June 11 for The State of CRISPR & Genome Editing. Sponsored by: